Navigation Links
Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence
Date:9/23/2008

Study Shows near 80% Improvement In Outcomes

PITTSBURGH, Sept. 23 /PRNewswire/ -- Radiation oncologists at Allegheny General Hospital (AGH) in Pittsburgh today will report to the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston that a newer, minimally invasive approach to treating high risk patients with Stage I non-small cell lung carcinoma (NSCLC) may significantly reduce the risk of local disease recurrence.

Developed at AGH over the past decade, the procedure involves removing only the cancerous section of the lung and enveloping the surgical site in a mesh material that is embedded with radioactive seeds. The seeds emit a low dose of radiation over a prolonged period of time in an effort to eradicate any remaining cancer cells.

Lung cancer is the leading cause of cancer death in the United States. Non-small cell lung carcinoma is the most common form of the disease, accounting for an estimated 85% of all cases. Stage I NSCLC is characterized by disease that is localized in the lung with no metastasis to the lymph node system.

"The standard of care for patients with this particular disease is a lobectomy, or surgical removal of the entire lobe of the lung. Many patients, however, are considered high risk for this procedure due to cardiopulmonary complications or other co-morbidities. In these cases, sublobar wedge resection is a more tolerable approach, but one that carries a much higher chance of local cancer recurrence," said Athanasios Colonias, MD, an AGH radiation oncologist and the study's principal investigator.

"Our study suggests that when intraoperative 125I Vicryl(R) mesh brachytherapy is added to sublobar resection, the local treatment failure rate is substantially reduced," Dr. Colonias said.

Dr. Colonias and his AGH colleagues examined the outcomes of 145 high-risk patients with Stage I NSCLC who underwent sublobar resection (SLR) with adjuvant intraoperative mesh brachytherapy between January 1996 to February 2008. Local treatment failure was defined as a cancer recurrence within the involved lobe.

At a median follow-up of 38 months, the AGH team documented just six local recurrences (4.1%) with the group, compared to an expected cancer recurrence rate of 20% with SLR only based on previously published data. No patient/tumor specific factors (age, histology, gender, stage, location of tumor, tumor size) or surgical/dosimetric factors (margin status, open vs. video assisted approach, total activity, number of seeds, dose prescribed, target area) were predictive of local recurrence. All of the procedures were well tolerated by patients with regard to pulmonary function and morbidity.

"Of the more than 150,000 people diagnosed each year with lung cancer, less than 20% are identified with disease in its earliest and most curable stage. For high risk patients, however, even a Stage I diagnosis poses significant therapeutic challenges and generally poor odds of a long-term recovery. It would appear that those odds may be improved considerably by combining sublobar resection with intraoperative mesh brachytherapy," said Robert Keenan, M.D., director of AGH's Center for Thoracic Surgery.

Dr. Keenan said a large, randomized multi-center clinical trial of SLR +/- brachytherapy is currently underway and will more definitively establish the efficacy of the procedure. The study is being coordinated by the American College of Surgeons Oncology Group and involves more than a dozen major U.S. Hospitals, including AGH.


'/>"/>
SOURCE Allegheny General Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Astro Meeting
2. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
3. Breast MRI Scan Could Determine Need for Radiation Therapy
4. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
7. St. Jude Study Finds Treatment With New Drug Might Make Tumor Cells More Sensitive to Therapy
8. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
9. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
10. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
11. New Research Shows Physical Therapy as Effective as Arthroscopic Knee Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):